Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Jorge Plutzky, M.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham & Women's Hospital
Cardiovascular Medicine, NRB 742
77 Avenue Louis Pasteur
Boston MA 02115
Phone6175254360, 4361
Fax617/525-4366

 Mentoring 
 completed student projects

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Liu S, Brown JD, Stanya KJ, Homan E, Leidl M, Inouye K, Bhargava P, Gangl MR, Dai L, Hatano B, Hotamisligil GS, Saghatelian A, Plutzky J, Lee CH. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature. 2013 Oct 23; 502(7472):550-4.
    View in: PubMed
  2. Nallamshetty S, Wang H, Rhee EJ, Kiefer FW, Brown JD, Lotinun S, Le P, Baron R, Rosen CJ, Plutzky J. Deficiency of Retinaldehyde Dehydrogenase 1 Induces BMP2 and Increases Bone Mass In Vivo. PLoS One. 2013; 8(8):e71307.
    View in: PubMed
  3. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. Cell. 2013 Aug 1; 154(3):569-82.
    View in: PubMed
  4. Zhang H, Plutzky J, Turchin A. Discontinuation of statins in routine care settings. Ann Intern Med. 2013 Jul 2; 159(1):75-6.
    View in: PubMed
  5. Khera AV, Plutzky J. Management of low levels of high-density lipoprotein-cholesterol. Circulation. 2013 Jul 2; 128(1):72-8.
    View in: PubMed
  6. Tatematsu S, Francis SA, Natarajan P, Rader DJ, Saghatelian A, Brown JD, Michel T, Plutzky J. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb Vasc Biol. 2013 Aug; 33(8):1788-94.
    View in: PubMed
  7. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2; 158(7):526-34.
    View in: PubMed
  8. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J. 2012 Nov; 164(5):672-80.
    View in: PubMed
  9. Kiefer FW, Cohen P, Plutzky J. Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. Circulation. 2012 Aug 28; 126(9):1012-5.
    View in: PubMed
  10. de Ferranti SD, Daniels SR, Gillman M, Vernacchio L, Plutzky J, Baker AL. NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: Can We Clarify the Controversy about Cholesterol Screening and Treatment in Childhood? Clin Chem. 2012 Dec; 58(12):1626-30.
    View in: PubMed
  11. Rhee EJ, Plutzky J. Retinoid metabolism and diabetes mellitus. Diabetes Metab J. 2012 Jun; 36(3):167-80.
    View in: PubMed
  12. Kiefer FW, Vernochet C, O'Brien P, Spoerl S, Brown JD, Nallamshetty S, Zeyda M, Stulnig TM, Cohen DE, Kahn CR, Plutzky J. Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. Nat Med. 2012 Jun; 18(6):918-25.
    View in: PubMed
  13. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012 Jun; 205 Suppl 3:S368-74.
    View in: PubMed
  14. Elmasri H, Ghelfi E, Yu CW, Traphagen S, Cernadas M, Cao H, Shi GP, Plutzky J, Sahin M, Hotamisligil G, Cataltepe S. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis. 2012 Sep; 15(3):457-68.
    View in: PubMed
  15. Kiefer FW, Orasanu G, Nallamshetty S, Brown JD, Wang H, Luger P, Qi NR, Burant CF, Duester G, Plutzky J. Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. Endocrinology. 2012 Jul; 153(7):3089-99.
    View in: PubMed
  16. Jain M, Plutzky J. Commentary. Clin Chem. 2012 May; 58(5):829-30.
    View in: PubMed
  17. Plutzky J. The incretin axis in cardiovascular disease. Circulation. 2011 Nov 22; 124(21):2285-9.
    View in: PubMed
  18. Shetty S, Ramos-Roman MA, Cho YR, Brown J, Plutzky J, Muise ES, Horton JD, Scherer PE, Parks EJ. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology. 2012 Jan; 153(1):113-22.
    View in: PubMed
  19. Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA Annu Symp Proc. 2011; 2011:1270-9.
    View in: PubMed
  20. Shabrova EV, Tarnopolsky O, Singh AP, Plutzky J, Vorsa N, Quadro L. Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice. PLoS One. 2011; 6(10):e24634.
    View in: PubMed
  21. Blaser BW, Kim HT, Alyea EP, Ho VT, Cutler C, Armand P, Koreth J, Antin JH, Plutzky J, Soiffer RJ. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
    View in: PubMed
  22. Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes. Am J Cardiol. 2011 Aug 2; 108(3 Suppl):25B-32B.
    View in: PubMed
  23. Davidson MH, Plutzky J. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 2; 108(3 Suppl):1B-2B.
    View in: PubMed
  24. Rhee EJ, Nallamshetty S, Plutzky J. Retinoid metabolism and its effects on the vasculature. Biochim Biophys Acta. 2012 Jan; 1821(1):230-40.
    View in: PubMed
  25. Brown JD, Oligino E, Rader DJ, Saghatelian A, Plutzky J. VLDL hydrolysis by hepatic lipase regulates PPARd transcriptional responses. PLoS One. 2011; 6(7):e21209.
    View in: PubMed
  26. Lee JH, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011 Jul; 17(7):812-5.
    View in: PubMed
  27. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011 Aug; 54(8):2132-42.
    View in: PubMed
  28. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011 Apr 15; 108(8):1002-16.
    View in: PubMed
  29. Chang K, Francis SA, Aikawa E, Figueiredo JL, Kohler RH, McCarthy JR, Weissleder R, Plutzky J, Jaffer FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010 Oct; 30(10):1933-9.
    View in: PubMed
  30. Fonseca VA, Zinman B, Nauck MA, Goldfine AB, Plutzky J. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med. 2010 Jul; 123(7):S2-S10.
    View in: PubMed
  31. Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, Krauss RM. VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res. 2010 Aug; 51(8):2275-81.
    View in: PubMed
  32. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, Lee RT. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes. 2010 Jun; 59(6):1424-34.
    View in: PubMed
  33. Brown J, Nallamshetty S, Plutzky J. Intersecting vectors of basic science research and clinical medicine: LOX-1? Clin Chem. 2010 Apr; 56(4):499-501.
    View in: PubMed
  34. Plutzky J. Expansion and contraction: the mighty, mighty fatty acid. Nat Med. 2009 Jun; 15(6):618-9.
    View in: PubMed
  35. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009 Feb 3; 53(5 Suppl):S35-42.
    View in: PubMed
  36. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T, Plutzky J. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest. 2009 Jan; 119(1):110-24.
    View in: PubMed
  37. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008 Nov 17; 102(10 Suppl):1K-34K.
    View in: PubMed
  38. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov; 5(4):319-35.
    View in: PubMed
  39. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008 Sep 2; 52(10):869-81.
    View in: PubMed
  40. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008 May 24; 371(9626):1800-9.
    View in: PubMed
  41. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008 Jun 13; 283(24):16477-87.
    View in: PubMed
  42. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. J Am Soc Nephrol. 2008 Jan; 19(1):4-7.
    View in: PubMed
  43. Plutzky J. A cardiologist's perspective on cardiometabolic risk. Am J Cardiol. 2007 Dec 17; 100(12A):3P-6P.
    View in: PubMed
  44. Ziouzenkova O, Plutzky J. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008 Jan 9; 582(1):32-8.
    View in: PubMed
  45. Plutzky J. Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha. Diab Vasc Dis Res. 2007 Sep; 4 Suppl 3:S12-4.
    View in: PubMed
  46. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med. 2007 Aug; 262(2):184-98.
    View in: PubMed
  47. Ziouzenkova O, Orasanu G, Sharlach M, Akiyama TE, Berger JP, Viereck J, Hamilton JA, Tang G, Dolnikowski GG, Vogel S, Duester G, Plutzky J. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med. 2007 Jun; 13(6):695-702.
    View in: PubMed
  48. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007 Aug; 1771(8):972-82.
    View in: PubMed
  49. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007 Jan 30; 115(4):518-33.
    View in: PubMed
  50. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72.
    View in: PubMed
  51. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 2; 115(1):114-26.
    View in: PubMed
  52. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol. 2007 Feb 19; 99(4A):27B-40B.
    View in: PubMed
  53. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006 Dec 19; 114(25):2871-91.
    View in: PubMed
  54. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19; 114(25):2850-70.
    View in: PubMed
  55. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006 Dec; 58(4):726-41.
    View in: PubMed
  56. Ziouzenkova O, Orasanu G, Sukhova G, Lau E, Berger JP, Tang G, Krinsky NI, Dolnikowski GG, Plutzky J. Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. Mol Endocrinol. 2007 Jan; 21(1):77-88.
    View in: PubMed
  57. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol. 2006 Aug; 26(8):1806-13.
    View in: PubMed
  58. Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 3; 98(4):490-8.
    View in: PubMed
  59. Lee CH, Plutzky J. Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? Circulation. 2006 Jan 3; 113(1):5-8.
    View in: PubMed
  60. Oligino E, Ziouzenkova O, Plutzky J. . VLDL hydrolysis by hepatic lipase is a distinct mechanism for PPAR-delta activation. Sarnoff Endowment, Washington, DC. 2006.
  61. Gornik HL, Plutzky J. . Dyslipidemia. In: Gaziano JM, editor. Atlas of Cardiovascular Risk Factors. 2005; 97-114.
  62. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care. 2005 May; 28(5):1145-50.
    View in: PubMed
  63. Plutzky J, Ziouzenkova O. . Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions. 2005.
  64. Orasanu G, Ziouzenkova O, Plutzky J. . Peroxisome proliferator activated receptors (PPARs) – potential targets for diabetic atherosclerosis. In: Cheta D, editor. Vascular Involvement in Diabetes. 2005; 35-49.
  65. Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2):147-73.
    View in: PubMed
  66. Plutzky J. . Peroxisome proliferator-activated receptors in diabetes, vascular inflammation, and atherosclerosis (DVD, audio tape). 2005.
  67. Devchand PR, Ziouzenkova O, Plutzky J. Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? Circ Res. 2004 Dec 10; 95(12):1137-9.
    View in: PubMed
  68. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord. 2004 Aug; 5(3):255-9.
    View in: PubMed
  69. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care. 2004 Jul; 7(4):369-75.
    View in: PubMed
  70. Plutzky J. PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction. Clin Cardiol. 2004 Jul; 27(7 Suppl 4):IV1-2.
    View in: PubMed
  71. Ahmed W, Ziouzenkova O, Orasanu G, Marchadier D, Rader D, Plutzky J. . Endothelial lipase acts on HDL to activate PPAR?. American Heart Association Scientific Sessions, New Orleans, LA. 2004.
  72. Ziouzenkova O, Plutzky J. . Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis. International Congress Series. 2004; 1262:147-151.
  73. Orasanu G, Ziouzenkova O, Ahmed W, Shoelson S, Plutzky J. Lipoprotein metabolism and uptake direct divergent peroxisome proliferator-activated receptor-? and hepatocyte nuclear factor 4? responses. American Heart Association Scientific Sessions, New Orleans, LA. 2004.
  74. Plutzky J. The vascular biology of atherosclerosis. Am J Med. 2003 Dec 8; 115 Suppl 8A:55S-61S.
    View in: PubMed
  75. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J Am Coll Cardiol. 2003 Nov 19; 42(10):1764-6.
    View in: PubMed
  76. Beckman J, Raji A, Plutzky J. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr Opin Cardiol. 2003 Nov; 18(6):479-85.
    View in: PubMed
  77. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology? Science. 2003 Oct 17; 302(5644):406-7.
    View in: PubMed
  78. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003 Aug 18; 92(4A):34J-41J.
    View in: PubMed
  79. Ziouzenkova O, Asatryan L, Sahady D, Orasanu G, Perrey S, Cutak B, Hassell T, Akiyama TE, Berger JP, Sevanian A, Plutzky J. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem. 2003 Oct 10; 278(41):39874-81.
    View in: PubMed
  80. Plutzky J. . PPARs and atherosclerosis. In: Duttaroy AK, Spener F, editors. Cellular proteins and their fatty acids in health and disease. 2003; Chapter 23.
  81. Plutzky J. Diabetes as a vascular disease. Dyslipidemia as a target. Postgrad Med. 2003 Apr; 113(4 Suppl):15-23.
    View in: PubMed
  82. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003 May 1; 23(5):859-63.
    View in: PubMed
  83. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, Plutzky J. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003 Mar 4; 100(5):2730-5.
    View in: PubMed
  84. Kramer D, Raji A, Plutzky J. Prediabetes mellitus and its links to atherosclerosis. Curr Diab Rep. 2003 Feb; 3(1):11-8.
    View in: PubMed
  85. Plutzky J, Libby P. . Pathophysiology of atherosclerotic heart disease. In: Tonkin AM, editor. Atherosclerosis and Heart Disease. 2003; 1-12.
  86. Plutzky J. . PPARs. In: Izzo JL, Black HR, editors. Hypertension Primer. 2003; 60-62.
  87. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002 Nov 26; 106(22):2760-3.
    View in: PubMed
  88. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications. 2002 Nov-Dec; 16(6):401-15.
    View in: PubMed
  89. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep. 2002 Nov; 4(6):514-21.
    View in: PubMed
  90. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood. 2002 Aug 15; 100(4):1340-6.
    View in: PubMed
  91. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002 Apr 5; 90(6):703-10.
    View in: PubMed
  92. Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J. Peroxisome proliferator-activated receptors. Curr Atheroscler Rep. 2002 Jan; 4(1):59-64.
    View in: PubMed
  93. Plutzky J, Libby P. . Diabetes and cardiovascular disease (DVD). 2002.
  94. Plutzky J. . The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease. Am J Cardiol. 2002; 90(7 ): 139-143.
  95. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001 Oct 18; 88(8A):10K-15K.
    View in: PubMed
  96. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol. 2001 Oct; 12(5):511-8.
    View in: PubMed
  97. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001 Aug; 8(4):203-10.
    View in: PubMed
  98. Plutzky J, Davidson J. . Diabetes and cardiovascular disease in the Hispanic population, (CD-ROM). 2001.
  99. Plutzky J, Ridker PM. Statins for stroke: the second story? Circulation. 2001 Jan 23; 103(3):348-50.
    View in: PubMed
  100. Marx N, Mackman N, Schönbeck U, Yilmaz N, Hombach V, Libby P, Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001 Jan 16; 103(2):213-9.
    View in: PubMed
  101. Plutzky J. . PPARs and diabetic atherosclerosis. 2001.
  102. Plutzky J. . Insulin resistance and atherosclerosis. 2001.
  103. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000 Nov; 15(6):416-21.
    View in: PubMed
  104. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000 Jul; 2(4):327-35.
    View in: PubMed
  105. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000 Jun 15; 164(12):6503-8.
    View in: PubMed
  106. Plutzky J. . PPARs and diabetic atherosclerosis. 2000.
  107. Plutzky J. . Atherosclerosis: an insulin resistance disorder. Proceedings from the Second Annual US/Japanese Dialogue on Lipids and Atherosclerosis. 2000; 245:49-58.
  108. Plutzky J, Libby P, Nakamura H. Second annual US/Japanese dialogue on lipids and atherosclerosis: towards an understanding of mechanism. 2000.
  109. Libby P, Aikawa M, Schoenbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. In: Stemme S, Olsson AG, editors. Atherosclerosis XII. 2000; 67-80.
  110. Libby P, Aikawa M, Schönbeck U, Sukhova G, Mach F, Marx N, Plutzky J. . Inflammation and plaque stability. 2000.
  111. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999 Oct; 6(5):337-46.
    View in: PubMed
  112. Kinlay S, Plutzky J. Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep. 1999 Sep; 1(3):238-43.
    View in: PubMed
  113. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol. 1999 Jul 8; 84(1A):15J-20J.
    View in: PubMed
  114. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999 Jun 22; 99(24):3125-31.
    View in: PubMed
  115. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999 Mar; 19(3):546-51.
    View in: PubMed
  116. Plutzky J. . Making sense of clinical trials in lipid lowering. Intensive review of internal medicine (CD-ROM). 1999.
  117. Plutzky J. . Coronary artery disease in the younger patient. New issues for the next millennium. 1999; 238:75-83.
  118. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998 Nov 30; 83(11):1097-103.
    View in: PubMed
  119. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998 Jul; 153(1):17-23.
    View in: PubMed
  120. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35.
    View in: PubMed
  121. Plutzky J. . Myocardial infarction in the younger patient. Cannon CP, editor. Management of acute coronary syndrome. 1998; 653-666. .
  122. Plutzky J. . Disorders of the heart and vascular system. Harrison’s Principles of Internal Medicine Self-Assessment and Review. 1998; 49-90. .
  123. Blumnethal RS, Plutzky J. Secondary prevention of myocardial infarction. Cannon CP, editor. Management of acute coronary syndrome. 1998; 695-704.
  124. Oberg K, Cannon C, Plutzky J. Focus on reteplase: a newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45.
  125. Freeman R, Plutzky J, Neel B, Rosenberg R. Methods for identifying a tyrosine phosphatase abnormally associated with neoplastic disease. 1996.
  126. Neel BG, Plutzky J, Rosenberg RD, Freeman RM, Lorenz U, Lechleider RJ. . Molecular cloning and characterization of a subfamily of nontransmembrane PTPs containing src homology 2 (SH2) domains. Adv Protein Phosphatases. 1993; 7:127-151.
  127. Freeman RM, Plutzky J, Neel BG. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A. 1992 Dec 1; 89(23):11239-43.
    View in: PubMed
  128. Plutzky J, Neel BG, Rosenberg RD, Eddy RL, Byers MG, Jani-Sait S, Shows TB. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics. 1992 Jul; 13(3):869-72.
    View in: PubMed
  129. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992 Feb 1; 89(3):1123-7.
    View in: PubMed
  130. Plutzky J. On being a physician. Am J Med. 1990 Aug; 89(2):252.
    View in: PubMed
  131. Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A. 1986 Feb; 83(3):546-50.
    View in: PubMed
  132. Beckmann RJ, Schmidt RJ, Santerre RF, Plutzky J, Crabtree GR, Long GL. The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res. 1985 Jul 25; 13(14):5233-47.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Plutzky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_